Avalanche Biotechnologies, Inc. (Avalanche) is a clinical-stage biotechnology company. The Company is focused on discovering and developing gene therapies for patients with sight-threatening ophthalmic diseases. The Company uses its gene therapy platform, the Ocular BioFactory, to create a pipeline of product candidates. The Company's product candidates include AVA-101, AVA-201 and AVA-311. The Company is developing its lead product candidate, AVA-101, which is indicated for the treatment for wet age-related macular degeneration (AMD). AVA-201 is the Company's next generation anti-vascular endothelial growth factor (anti-VEGF) gene therapy product candidate, which it is developing for the prevention of wet AMD. The Company is conducting preclinical studies on AVA-311 for the treatment of Juvenile X-linked Retinoschisis (XLRS).